Ouabain: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Student, David Canner, Alexander Berchansky

Revision as of 01:07, 5 January 2012 view source David Canner (talk \| contribs) 7,699 edits No edit summary ← Older edit		Revision as of 15:47, 3 September 2015 view source Alexander Berchansky (talk \| contribs) 29,637 edits No edit summary Newer edit →
Line 1:		Line 1:
	<StructureSection load='3n23' size='~~500~~' side='right' caption='Na+/K+ ATPase-Ouabain Binding, ([[3n23]])' scene='Sandbox_60/Ouabain_3d/1'>		<StructureSection load='3n23' size='450' side='right' caption='Na+/K+ ATPase-Ouabain Binding, ([[3n23]])' scene='Sandbox_60/Ouabain_3d/1'>
	[[Ouabain]] is a cardiac glycoside that inhibits ATP-dependent sodium-potassium exchange across cell membranes. The binding of ouabain to the sodium-potassium pump (also called Na+/K+ ATPase) prevents the conformational changes necessary for its proper function. This affects intracellular ion composition in various ways with various effects, depending on the cell and the dosage. The compound has therefore been utilized in medicine, both as a [[Pharmaceutical Drugs\|therapeutic]] and in research related to active [[Membrane Channels\|active membrane transport]].		[[Ouabain]] is a cardiac glycoside that inhibits ATP-dependent sodium-potassium exchange across cell membranes. The binding of ouabain to the sodium-potassium pump (also called Na+/K+ ATPase) prevents the conformational changes necessary for its proper function. This affects intracellular ion composition in various ways with various effects, depending on the cell and the dosage. The compound has therefore been utilized in medicine, both as a [[Pharmaceutical Drugs\|therapeutic]] and in research related to active [[Membrane Channels\|active membrane transport]].